Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Context Therapeutics Q2 EPS $(0.25)

Context Therapeutics Q2 EPS $(0.25)

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.25) per share.

byBenzinga Newsdesk

August 11, 2022

1 minute read

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.25) per share.

Earnings

Earnings Preview For Sensus Healthcare

By Benzinga Insights

February 7, 3:02 PM

Sensus Healthcare (NASDAQ:SRTS) is set to give its latest quarterly earnings report on Thursday, 2024-02-08. Here’s what investors…

SRTS

News

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

By Michael Horton

August 30, 6:01 PM

GT Biopharma, Inc. (the "Company" or "GTB") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer

GTBP

B of A Securities Maintains Neutral on Micron Technology, Lowers Price Target to $58

By Benzinga Newsdesk

September 30, 8:21 AM

B of A Securities analyst Vivek Arya maintains Micron Technology (NASDAQ:MU) with a Neutral and lowers the price target from $62 to $58.

Over $152M Crypto Shorts Liquidated As Bitcoin, Ethereum Spike

By Mehab Qureshi

March 13, 1:40 AM

The total cryptocurrency market cap climbed back above $1 trillion in the last 24 hours.

$ADA

Context Therapeutics Q2 EPS $(0.25)

Related Posts

Earnings Preview For Sensus Healthcare

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

B of A Securities Maintains Neutral on Micron Technology, Lowers Price Target to $58

Over $152M Crypto Shorts Liquidated As Bitcoin, Ethereum Spike